SCHEMBL5652807

SCHEMBL5652807

CCOc1cc(C(=O)NN2CCCCC2)ccc1-c1nc2ncccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 15/20 0.53
PDE4A P27815 8/20 0.45
PDE4B Q07343 8/20 0.45
PDE4C Q08493 8/20 0.45
PDE4D Q08499 8/20 0.45
PDE2A O00408 1/20 0.45
AURKA O14965 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
HPGD P15428 1/20 0.43
PDE3B Q13370 1/20 0.43
PDE3A Q14432 1/20 0.43
HSD17B10 Q99714 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5651844 0.91 PDE2A (0.56) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL5652928 0.87 HPSE (0.53) PDE5AMEN1KMT2APOLBHTT
SCHEMBL5653824 0.86 AURKA (0.45) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL5650901 0.84 AURKA (0.45) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL5653967 0.84 AURKA (0.45) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL5650806 0.84 SIRT2 (0.46) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL5648605 0.82 RHEB (0.45) MEN1KMT2APOLBHTTSMN1; SMN2
SCHEMBL5648702 0.81 SIRT2 (0.47) MEN1KMT2APOLBHTTSMN1; SMN2
SCHEMBL5650184 0.80 HPSE (0.45) MEN1KMT2APOLBHTTSMN1; SMN2
SCHEMBL5651444 0.80 PRMT5 (0.59) AURKAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 PDE5A 3793/4885PDE4A 4250/4885PDE4B 3559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.